Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Judge Orders $5.8 Million Payment to E. Jean Carroll After Trump Loses Appeal Bid 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
US Egg Producers Settle Price Manipulation Probe, Agree to Pay $3.3 Million and Donate 53 Million Eggs 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Trump Administration Hands Over Key Evidence in Minnesota Immigration Shooting Investigations 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
ICC Says Darfur War Crimes Probe Reaches Breakthrough in Sudan Investigation 
Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Sanofi, accusing the company of unlawfully incentivizing healthcare providers to prescribe its medications instead of competing alternatives. According to the attorney general’s office, Sanofi allegedly created service-based programs for healthcare professionals that effectively functioned as bribes, in violation of the Texas Health Care Program Fraud Prevention Act.
State officials claim these programs were designed to improperly influence prescribing decisions, potentially impacting fair competition and patient care within Texas healthcare programs. The lawsuit seeks more than $1 million in monetary relief, including civil penalties, as well as a court injunction to prevent any further alleged unlawful conduct.
Sanofi has strongly denied the allegations. In a public statement, the company asserted that its services are fully structured to comply with both federal and state regulations. Sanofi emphasized that the programs are intended to support patient care and improve health outcomes, not to sway physicians’ prescribing behavior. The company also stated that the state’s legal action does not reflect the merits of the case and confirmed it will vigorously defend itself in court.
This is not the first time Attorney General Paxton has taken legal action against major pharmaceutical companies. Previously, Texas sued Sanofi and Bristol-Myers Squibb, alleging they failed to disclose that their blood thinner Plavix was less effective for certain patients. In a separate case last year, the state filed a lawsuit against Eli Lilly, accusing the drugmaker of bribing healthcare providers to prescribe its top-selling medications, including GLP-1 drugs Mounjaro and Zepbound.
The latest lawsuit highlights Texas’ continued scrutiny of pharmaceutical industry practices, particularly regarding alleged healthcare fraud, drug marketing tactics, and compliance with state healthcare laws.
